Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669630 | PMC |
| http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.10.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developing Topics.
Alzheimers Dement
December 2024
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China.
Background: Microglia play a critical role in the pathogenesis and development of Alzheimer's disease (AD). Selective small-molecule colony-stimulating factor 1 receptors (CSF1R) inhibitor, designed to deplete microglia, could be used to meliorate AD. This study aimed to investigate the effects and mechanisms of chimeric antigen receptor T (CAR-T) cells targeting CSF1R in 6-month-old APP/PS1 male mice.
View Article and Find Full Text PDFNovel Treatment Options for Multiple Myeloma.
JCO Oncol Pract
January 2025
Fred Hutchinson Cancer Center, Seattle, WA.
Multiple myeloma (MM), the second most common hematologic malignancy in the United States, is characterized by repeated cycles of remission and relapse, with increasing resistance to treatment after each line of therapy. Despite the virtually incurable nature of MM, recent therapeutic breakthroughs have fundamentally reshaped its treatment landscape. This review explores evolving care paradigms, spanning from newly diagnosed MM to relapsed or refractory disease.
View Article and Find Full Text PDFSmart Cell Therapy: an industry perspective on macrophages as living drugs.
Cytotherapy
December 2024
Barcia Novel Therapies, Lexington, Massachusetts, USA. Electronic address:
Macrophage-based cell therapies represent a cutting-edge frontier in immunotherapy, offering distinct advantages over conventional approaches like CAR-T. This review explores the potential of macrophages to orchestrate both innate and adaptive immune responses, enhancing the body's ability to combat diseases locally and systemically. Dubbed a "Smart Cell Therapy," macrophages can initiate and coordinate complex immunological cascades, leveraging multiple immune system components while also performing effector functions.
View Article and Find Full Text PDFImmunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments.
Pharmaceuticals (Basel)
November 2024
Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Bone metastases are a prevalent complication in advanced cancers, particularly in breast, prostate, and lung cancers, and are associated with severe skeletal-related events (SREs), including fractures, spinal cord compression, and debilitating pain. Conventional bone-targeted treatments like bisphosphonates and RANKL inhibitors (denosumab) reduce osteoclast-mediated bone resorption but do not directly impact tumor progression within the bone. This review focuses on examining the growing potential of immunotherapy in targeting the unique challenges posed by bone metastases.
View Article and Find Full Text PDFMechanisms of Cbl-Mediated Ubiquitination of Proteins in T and Natural Killer Cells and Effects on Immune Cell Functions.
Life (Basel)
December 2024
The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben Gurion University of the Negev, P.O. Box 653, Beer Sheva 84105, Israel.
Post-translational ubiquitination is an essential mechanism for the regulation of protein stability and function, which contributes to the regulation of the immune system. Cbl, an E3 ubiquitin ligase, is particularly well-characterized in the context of T and NK cell signaling, where it serves as a key regulator of receptor downstream signaling events and as a modulator of cell activation. Cbl promotes the proteasomal degradation of TCR/CD3 subunits as well as the protein kinases Fyn and Lck in T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!